Kane Biotech Receives Decisions to Grant for Two European Patents Providing Broad Protection of coactiv+™ Technology for Wound Care, Skin Infections and Personal Care Formulations Jul 29, 2021
Kane Biotech Expands its Wound Care and Surgical Portfolio with a coactiv+TM Antimicrobial Hydrogel Jul 22, 2021
Kane Biotech announces two key milestones as DispersinB® wound care project advances towards human clinical trials Jul 13, 2021
Kane Biotech Announces Adoption of Performance and Restricted Share Unit Plan and Amended and Restated Stock Option Plan Jun 9, 2021
Kane Biotech to Release First Quarter 2021 Financial Results on May 27 – Conference Call to Follow May 20, 2021
